| Primary | Change From Baseline in Behavior Rating Inventory of Executive Function - Adult Version Global Executive Composite T-score (BRIEF-A GEC T) at Week 9, Last Observation Carried Forward (LOCF) | BRIEF-A Global Executive Composite assesses behavioral aspects of executive function. Items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment. | The Full Analysis Set (FAS) defined as all randomized subjects who took at least 1 dose of randomized investigational product and had at least 1 primary efficacy assessment after baseline. | Posted | | Least Squares Mean | Standard Error | T-scores | | Baseline and week 9 | | | | ID | Title | Description |
|---|
| OG000 | Lisdexamfetamine Dimesylate (LDX) | Lisdexamfetamine Dimesylate (LDX, SPD489) is administered orally once-daily at doses of either 20, 30, 40, 50, 60, or 70 mg for 9 weeks. | | OG001 | Placebo | Administered orally once-daily for 9 weeks. |
| | | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG000-21.2± 1.67
- OG001-13.2± 1.66
|
|
| | Group IDs | Group Description | Statistical Method | Statistical Comment | P-Value | P-Value Comment | Parameter Type | Parameter Value | Dispersion Type | Dispersion Value | Confidence Interval Sides | Confidence Interval % | CI Lower Limit | CI Upper Limit | CI Lower Limit Comment | CI Upper Limit Comment | Estimate Comment | Tested Non-Inferiority | Non-Inferiority Type | Non-Inferiority Comment | Other Analysis Description |
|---|
| | ANCOVA | | 0.0009 | | Mean Difference (Final Values) | -8.0 | | | 2-Sided | 95 | -12.7 | -3.3 | | | | | Superiority or Other (legacy) | | |
|
| Secondary | Change From Baseline in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score at Week 9 - (LOCF) | MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression. | | Posted | | Least Squares Mean | Standard Error | Scores on a scale | | Baseline and week 9 | | | | ID | Title | Description |
|---|
| OG000 | Lisdexamfetamine Dimesylate (LDX) | Lisdexamfetamine Dimesylate (LDX, SPD489) is administered orally once-daily at doses of either 20, 30, 40, 50, 60, or 70 mg for 9 weeks. | | OG001 | Placebo | Administered orally once-daily for 9 weeks. |
| |
| Secondary | Change From Baseline in BRIEF-A T-scores at Week 9, LOCF | BRIEF-A is a validated 75-item questionnaire. Items are rated 1 (never), 2 (sometimes), and 3 (often). There is no range for a total score. Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment. | | Posted | | Least Squares Mean | Standard Error | T-scores | | Baseline and week 9 | | | | ID | Title | Description |
|---|
| OG000 | Lisdexamfetamine Dimesylate (LDX) | Lisdexamfetamine Dimesylate (LDX, SPD489) is administered orally once-daily at doses of either 20, 30, 40, 50, 60, or 70 mg for 9 weeks. | | OG001 | Placebo | Administered orally once-daily for 9 weeks. |
| |
| Secondary | Change From Baseline in Central Nervous System Vital Signs Computerized Cognitive Testing Battery Neurocognitive Domain and Index Scores at up to 9 Weeks/Endpoint | This measures the speed and accuracy of basic mental functions. Scores are normalized from raw scores and present an age matched score relative to other people in a normative sample. Scores are normalized with a mean of 100 and standard deviation of 15. Scores < 70 indicate likely deficit and impairment, and scores > 110 indicate high function and capacity. Higher scores are better. | | Posted | | Mean | Standard Deviation | Response scores | | Baseline and up to 9 weeks/Endpoint | | | | ID | Title | Description |
|---|
| OG000 | Lisdexamfetamine Dimesylate (LDX) | Lisdexamfetamine Dimesylate (LDX, SPD489) is administered orally once-daily at doses of either 20, 30, 40, 50, 60, or 70 mg for 9 weeks. | | OG001 | Placebo | Administered orally once-daily for 9 weeks. |
| |
| Secondary | Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Baseline | CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill) | | Posted | | Number | | percentage of participants | | Baseline | | | | ID | Title | Description |
|---|
| OG000 | Lisdexamfetamine Dimesylate (LDX) | Lisdexamfetamine Dimesylate (LDX, SPD489) is administered orally once-daily at doses of either 20, 30, 40, 50, 60, or 70 mg for 9 weeks. | | OG001 | Placebo | Administered orally once-daily for 9 weeks. |
| |
| Secondary | Percent of Participants With CGI-S at up to 9 Weeks/Endpoint | CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill) | FAS population was used for this assessment. However, not all subjects from the FAS completed this assessment, therefore the total number of subjects analyzed for this outcome is less than the total number of subjects that comprise the FAS population. | Posted | | Number | | percentage of participants | | Up to 9 weeks/Endpoint | | | | ID | Title | Description |
|---|
| OG000 | Lisdexamfetamine Dimesylate (LDX) | Lisdexamfetamine Dimesylate (LDX, SPD489) is administered orally once-daily at doses of either 20, 30, 40, 50, 60, or 70 mg for 9 weeks. | | OG001 | Placebo | Administered orally once-daily for 9 weeks. |
| |
| Secondary | Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) at Week 9, LOCF | Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. | | Posted | | Number | | percentage of participants | | Week 9 | | | | ID | Title | Description |
|---|
| OG000 | Lisdexamfetamine Dimesylate (LDX) | Lisdexamfetamine Dimesylate (LDX, SPD489) is administered orally once-daily at doses of either 20, 30, 40, 50, 60, or 70 mg for 9 weeks. | | OG001 | Placebo | Administered orally once-daily for 9 weeks. |
| |
| Secondary | Change From Baseline in Endicott Work Productivity Scale (EWPS) Total Score at up to 9 Weeks/Endpoint | The EWPS quantifies work performance, productivity attitudes and behaviors assessing 25 items on a scale ranging from 0 (high performance) to 4 (lowest performance). Scores range from 0 to 100 with 100 representing lowest productivity. | FAS population was used for this assessment. However, not all subjects from the FAS completed this assessment, therefore the total number of subjects analyzed for this outcome is less than the total number of subjects that comprise the FAS population. | Posted | | Least Squares Mean | Standard Error | Scores on a scale | | Baseline and up to 9 weeks/Endpoint | | | | ID | Title | Description |
|---|
| OG000 | Lisdexamfetamine Dimesylate (LDX) | Lisdexamfetamine Dimesylate (LDX, SPD489) is administered orally once-daily at doses of either 20, 30, 40, 50, 60, or 70 mg for 9 weeks. | | OG001 | Placebo | Administered orally once-daily for 9 weeks. |
| |
| Secondary | Change From Baseline in Changes in Sexual Functioning Questionnaire (CSFQ-14) Total Scores for Males at Week 9, LOCF | This is a 14 item self-report tool that evaluates sexual functioning. Each item is scored on a 5-point Likert scale ranging from 1 (never) to 5 (always) with total scores ranging from 14 to 70. Higher scores reflect better sexual functioning. | The Safety Analysis Set (SAS) defined as all randomized subjects who took at least 1 dose of investigational product and for whom at least 1 follow-up safety assessment was completed. Only the males from the SAS population were used and not all of them completed this outcome assessment. | Posted | | Mean | Standard Deviation | Scores on a scale | | Baseline and week 9 | | | | ID | Title | Description |
|---|
| OG000 | Lisdexamfetamine Dimesylate (LDX) | Lisdexamfetamine Dimesylate (LDX, SPD489) is administered orally once-daily at doses of either 20, 30, 40, 50, 60, or 70 mg for 9 weeks. | | OG001 | Placebo | Administered orally once-daily for 9 weeks. |
| |
| Secondary | Change From Baseline in CSFQ-14 Total Scores for Females at Week 9, LOCF | This is a 14 item self-report tool that evaluates sexual functioning. Each item is scored on a 5-point Likert scale ranging from 1 (never) to 5 (always) with total scores ranging from 14 to 70. Higher scores reflect better sexual functioning. | Only the females from the SAS population were used and not all of them completed this outcome assessment. | Posted | | Mean | Standard Deviation | Scores on a scale | | Baseline and week 9 | | | | ID | Title | Description |
|---|
| OG000 | Lisdexamfetamine Dimesylate (LDX) | Lisdexamfetamine Dimesylate (LDX, SPD489) is administered orally once-daily at doses of either 20, 30, 40, 50, 60, or 70 mg for 9 weeks. | | OG001 | Placebo | Administered orally once-daily for 9 weeks. |
| |
| Secondary | Change From Baseline in Short Form-12 Health Survey (SF-12) Scale Total Scores at Week 9 | The SF-12 is a 12-item self-report questionnaire that is a subset of the SF-36 Health Survey. The survey captures physical and mental health. Each of the 12 items is scored using various scales with a total score ranging from 0 (lowest level of health) to 100 (highest level of health). | FAS population was used for this assessment. However, not all subjects from the FAS completed this assessment, therefore the total number of subjects analyzed for this outcome is less than the total number of subjects that comprise the FAS population. | Posted | | Mean | Standard Deviation | Scores on a scale | | Baseline and week 9 | | | | ID | Title | Description |
|---|
| OG000 | Lisdexamfetamine Dimesylate (LDX) | Lisdexamfetamine Dimesylate (LDX, SPD489) is administered orally once-daily at doses of either 20, 30, 40, 50, 60, or 70 mg for 9 weeks. | | OG001 | Placebo | Administered orally once-daily for 9 weeks. |
| |
| Secondary | Change From Baseline in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Total Scores at up to 9 Weeks/Endpoint | The Q-LES-Q is a 93-item self-report questionnaire on quality of life and health. Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good) with a total score ranging from 93 to 465. Higher scores indicate greater satisfaction. | FAS population was used for this assessment. However, not all subjects from the FAS completed this assessment, therefore the total number of subjects analyzed for this outcome is less than the total number of subjects that comprise the FAS population. | Posted | | Mean | Standard Deviation | Scores on a scale | | Baseline and up to 9 weeks/Endpoint | | | | ID | Title | Description |
|---|
| OG000 | Lisdexamfetamine Dimesylate (LDX) | Lisdexamfetamine Dimesylate (LDX, SPD489) is administered orally once-daily at doses of either 20, 30, 40, 50, 60, or 70 mg for 9 weeks. | | OG001 | Placebo | Administered orally once-daily for 9 weeks. |
| |
| Secondary | Change From Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at Week 11 | ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity. | SAS population was used for this assessment. However, not all subjects from the SAS completed this assessment, therefore the total number of subjects analyzed for this outcome is less than the total number of subjects that comprise the SAS population. | Posted | | Mean | Standard Deviation | Scores on a scale | | Baseline and week 11 | | | | ID | Title | Description |
|---|
| OG000 | Lisdexamfetamine Dimesylate (LDX) | Lisdexamfetamine Dimesylate (LDX, SPD489) is administered orally once-daily at doses of either 20, 30, 40, 50, 60, or 70 mg for 9 weeks. | | OG001 | Placebo | Administered orally once-daily for 9 weeks. |
| |
| Secondary | Change From Baseline in the Generalized Anxiety Disorder 7-Item (GAD-7) Total Score at Week 9, LOCF | The GAD-7 is a 7-item self-report questionnaire for assessing anxiety severity. Each item is scored using a scale that ranges from 0 (not at all) to 3 (nearly every day) with total scores ranging from 0 to 21. Lower scores indicate a reduction in anxiety. | | Posted | | Mean | Standard Deviation | Scores on a scale | | Baseline and week 9 | | | | ID | Title | Description |
|---|
| OG000 | Lisdexamfetamine Dimesylate (LDX) | Lisdexamfetamine Dimesylate (LDX, SPD489) is administered orally once-daily at doses of either 20, 30, 40, 50, 60, or 70 mg for 9 weeks. | | OG001 | Placebo | Administered orally once-daily for 9 weeks. |
| |
| Secondary | Change From Baseline in Sheehan Suicidality Tracking Scale (STS) Total Score at Week 9 | The STS is an 8-question clinician-rated assessment of suicidal ideation, suicidal behavior, and accidents. The items are scored on a 5-point Likert scale from 0 (not at all) to 4 (extremely) and summed to produce a total score ranging from 0 to 32. Lower scores indicate reduced suicidal tendencies. | SAS population was used for this assessment. However, not all subjects from the SAS completed this assessment, therefore the total number of subjects analyzed for this outcome is less than the total number of subjects that comprise the SAS population. | Posted | | Mean | Standard Deviation | Scores on a scale | | Baseline and week 9 | | | | ID | Title | Description |
|---|
| OG000 | Lisdexamfetamine Dimesylate (LDX) | Lisdexamfetamine Dimesylate (LDX, SPD489) is administered orally once-daily at doses of either 20, 30, 40, 50, 60, or 70 mg for 9 weeks. | | OG001 | Placebo | Administered orally once-daily for 9 weeks. |
| |